Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 8 | 2024 | 3493 | 1.130 |
Why?
|
| Brain Neoplasms | 13 | 2024 | 9071 | 1.050 |
Why?
|
| Indigofera | 1 | 2023 | 2 | 0.890 |
Why?
|
| Radiosurgery | 3 | 2021 | 1328 | 0.740 |
Why?
|
| Spinal Neoplasms | 2 | 2018 | 708 | 0.740 |
Why?
|
| Nucleotides | 1 | 2023 | 451 | 0.700 |
Why?
|
| Lymphopenia | 1 | 2022 | 297 | 0.680 |
Why?
|
| Neoplasms | 8 | 2024 | 22340 | 0.560 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 2017 | 31 | 0.560 |
Why?
|
| Neurosciences | 1 | 2022 | 385 | 0.550 |
Why?
|
| Research Report | 1 | 2018 | 367 | 0.470 |
Why?
|
| Palliative Care | 3 | 2020 | 3645 | 0.470 |
Why?
|
| Isocitrate Dehydrogenase | 5 | 2024 | 954 | 0.460 |
Why?
|
| Leukemia | 1 | 2022 | 1522 | 0.450 |
Why?
|
| Phenylacetates | 1 | 2014 | 112 | 0.450 |
Why?
|
| Radiation Injuries | 1 | 2020 | 1181 | 0.410 |
Why?
|
| Receptors, GABA | 1 | 2014 | 312 | 0.380 |
Why?
|
| Radiation Oncology | 1 | 2018 | 569 | 0.380 |
Why?
|
| Rectal Neoplasms | 1 | 2020 | 1182 | 0.380 |
Why?
|
| Spinal Fractures | 1 | 2018 | 703 | 0.370 |
Why?
|
| Joint Instability | 1 | 2018 | 802 | 0.350 |
Why?
|
| Pain Measurement | 1 | 2020 | 3561 | 0.340 |
Why?
|
| Photons | 1 | 2014 | 572 | 0.340 |
Why?
|
| Neurotransmitter Agents | 1 | 2014 | 663 | 0.330 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 2895 | 0.310 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8529 | 0.310 |
Why?
|
| Glioblastoma | 1 | 2022 | 3459 | 0.280 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2014 | 1140 | 0.280 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 1462 | 0.270 |
Why?
|
| Mortality | 1 | 2017 | 2904 | 0.260 |
Why?
|
| Medical Oncology | 1 | 2018 | 2339 | 0.260 |
Why?
|
| Patient Selection | 1 | 2018 | 4255 | 0.250 |
Why?
|
| Pain | 1 | 2020 | 5077 | 0.250 |
Why?
|
| Karnofsky Performance Status | 3 | 2020 | 163 | 0.230 |
Why?
|
| DNA Damage | 2 | 2024 | 2457 | 0.220 |
Why?
|
| Salicylanilides | 1 | 2022 | 15 | 0.210 |
Why?
|
| Radiotherapy Dosage | 2 | 2021 | 2865 | 0.200 |
Why?
|
| Anxiety | 1 | 2017 | 4671 | 0.190 |
Why?
|
| Melanoma | 1 | 2020 | 5719 | 0.190 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2022 | 113 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2024 | 377 | 0.180 |
Why?
|
| Dacarbazine | 1 | 2022 | 552 | 0.170 |
Why?
|
| Transaminases | 1 | 2018 | 199 | 0.140 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2017 | 94 | 0.140 |
Why?
|
| Histone Code | 1 | 2018 | 159 | 0.140 |
Why?
|
| Depression | 1 | 2017 | 8237 | 0.140 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2018 | 169 | 0.140 |
Why?
|
| Flushing | 1 | 2017 | 52 | 0.140 |
Why?
|
| Triazoles | 1 | 2022 | 897 | 0.140 |
Why?
|
| Humans | 25 | 2024 | 765968 | 0.130 |
Why?
|
| Workflow | 1 | 2021 | 862 | 0.130 |
Why?
|
| Necrosis | 1 | 2020 | 1617 | 0.120 |
Why?
|
| Indoles | 1 | 2023 | 1839 | 0.120 |
Why?
|
| Carcinoid Tumor | 1 | 2017 | 225 | 0.120 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 580 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 1776 | 0.120 |
Why?
|
| Mutation | 7 | 2024 | 30198 | 0.120 |
Why?
|
| Retinoblastoma Protein | 1 | 2018 | 666 | 0.110 |
Why?
|
| Photochemical Processes | 1 | 2014 | 84 | 0.110 |
Why?
|
| Drug Stability | 1 | 2014 | 288 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2018 | 3181 | 0.100 |
Why?
|
| DNA | 2 | 2024 | 7202 | 0.100 |
Why?
|
| Glutamic Acid | 1 | 2018 | 1180 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2024 | 3081 | 0.100 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 1643 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 3537 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 3715 | 0.100 |
Why?
|
| Kidney Neoplasms | 2 | 2018 | 4274 | 0.090 |
Why?
|
| Patch-Clamp Techniques | 1 | 2014 | 918 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 961 | 0.090 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 59489 | 0.090 |
Why?
|
| Spine | 1 | 2018 | 1128 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2017 | 1272 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2017 | 1494 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2022 | 3047 | 0.090 |
Why?
|
| Diarrhea | 1 | 2017 | 1316 | 0.080 |
Why?
|
| Glutarates | 2 | 2024 | 243 | 0.080 |
Why?
|
| Molecular Structure | 1 | 2014 | 1885 | 0.080 |
Why?
|
| Pituitary Neoplasms | 1 | 2018 | 1321 | 0.080 |
Why?
|
| Qualitative Research | 1 | 2020 | 3139 | 0.080 |
Why?
|
| Female | 12 | 2022 | 396112 | 0.080 |
Why?
|
| Middle Aged | 10 | 2020 | 223009 | 0.080 |
Why?
|
| Interneurons | 1 | 2014 | 593 | 0.080 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3946 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2020 | 10070 | 0.080 |
Why?
|
| Adult | 9 | 2023 | 223044 | 0.080 |
Why?
|
| Orthopedic Procedures | 1 | 2018 | 1280 | 0.070 |
Why?
|
| Evoked Potentials | 1 | 2014 | 1048 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2020 | 24282 | 0.070 |
Why?
|
| Synaptic Transmission | 1 | 2014 | 1175 | 0.070 |
Why?
|
| Male | 10 | 2020 | 363698 | 0.070 |
Why?
|
| Aged | 8 | 2020 | 171117 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 5337 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2822 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2017 | 2074 | 0.070 |
Why?
|
| Cerebellum | 1 | 2014 | 1518 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2020 | 81514 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3596 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 8041 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2021 | 3458 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 2371 | 0.060 |
Why?
|
| Animals | 6 | 2024 | 168764 | 0.050 |
Why?
|
| Consensus | 2 | 2024 | 3202 | 0.050 |
Why?
|
| Mice | 4 | 2024 | 81819 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 21056 | 0.050 |
Why?
|
| Nucleotidyltransferases | 1 | 2024 | 242 | 0.050 |
Why?
|
| Prognosis | 5 | 2020 | 29922 | 0.050 |
Why?
|
| Tumor Escape | 1 | 2024 | 371 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 9601 | 0.040 |
Why?
|
| DNA Transposable Elements | 1 | 2024 | 765 | 0.040 |
Why?
|
| Young Adult | 4 | 2018 | 59889 | 0.040 |
Why?
|
| Genes, Retinoblastoma | 1 | 2018 | 125 | 0.040 |
Why?
|
| Pregnancy Proteins | 1 | 2018 | 225 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2018 | 303 | 0.030 |
Why?
|
| Heart Septal Defects | 1 | 2018 | 191 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 65188 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 13451 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 54802 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 12056 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1153 | 0.030 |
Why?
|
| Integrases | 1 | 2018 | 520 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 385 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2021 | 933 | 0.030 |
Why?
|
| DNA Repair | 1 | 2024 | 2048 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2024 | 17075 | 0.030 |
Why?
|
| Transgenes | 1 | 2018 | 1015 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 12509 | 0.030 |
Why?
|
| Estrogens | 1 | 2020 | 1529 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2018 | 963 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 36532 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 74840 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 1153 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3608 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2018 | 2218 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2018 | 3586 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2018 | 1530 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 3819 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2024 | 4424 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 2593 | 0.020 |
Why?
|
| Propensity Score | 1 | 2017 | 1968 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 3737 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6499 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 2056 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2020 | 3615 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2018 | 4159 | 0.020 |
Why?
|
| Cause of Death | 1 | 2018 | 3708 | 0.020 |
Why?
|
| Homeostasis | 1 | 2018 | 3336 | 0.020 |
Why?
|
| Alleles | 1 | 2018 | 6897 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 39193 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 88835 | 0.020 |
Why?
|
| Echocardiography | 1 | 2018 | 5045 | 0.020 |
Why?
|
| Survival Rate | 1 | 2018 | 12795 | 0.010 |
Why?
|
| Cytokines | 1 | 2018 | 7421 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2018 | 4752 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 18293 | 0.010 |
Why?
|
| Disease Progression | 1 | 2017 | 13632 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 22332 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9373 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 13462 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 41649 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 40065 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13648 | 0.010 |
Why?
|
Concepts
(162)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(79)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_